SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-006126
Filing Date
2020-03-12
Accepted
2020-03-12 16:27:44
Documents
3
Period of Report
2020-03-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea119470-8k_relmada.htm 8-K 30381
2 EMPLOYMENT AGREEMENT, DATED MARCH 7, 2020, BY AND BETWEEN THOMAS WESSEL AND RELM ea119470ex10-1_relmada.htm EX-10.1 29931
3 GRAPHIC ex10-1_001.jpg GRAPHIC 12528
  Complete submission text file 0001213900-20-006126.txt   79066
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 20709162
SIC: 2834 Pharmaceutical Preparations